INFLUENCE OF THE IMIQUIMOD ON THE INTERFERON PRODUCTION AND TREATMENT OF THE EXPERIMENTAL HERPES SIMPLEX VIRUS INFECTION

Cover Page


Cite item

Full Text

Abstract

Background. Imiquimod is an imidazole derivative acting as an immunomodulator on the level of innate and adaptive immune system. Our objective was to evaluate the antiviral activity of generically reproduced imiquimod administered subcutaneously in mice and intravaginally in guinea pigs against herpes simplex virus (HSV), as well as to study the dynamics of serum interferon (IFN) synthesis under different dosing regimens. Results. When administered subcutaneously at doses of 0.5, 1.0 and 10 mg/kg imiquimod increased IFN production in mice in a dose-dependent manner with maximum serum IFN concentrations occurring 4 hours after dosing. Imiquimod protected mice from intraperitoneal HSV infection at doses of 3.2 and 32 LD50.The utmost protection (100% survival) was observed when imiquimod was administered at a dose of 100 mg/kg daily for 5 days before infection. Topical application of imiquimod 5% cream exhibited significantly more rapid and complete virus elimination in guinea pigs intravaginally infected with HSV type 2 compared to control group. Conclusion. Imiquimod produced as a generic possesses the same immunomodulatory and antiviral properties as the originally synthesized substance.

About the authors

V. S. Smirnov

Biomedical Research and Production Complex «Cytomed»

Author for correspondence.
Email: vssmi@mail.ru
Russian Federation

S. V. Petlenko

Biomedical Research and Production Complex «Cytomed»

Email: noemail@neicon.ru
Russian Federation

References

  1. Лебедев К.А., Понякина И.Д. Иммунология образраспознающих рецепторов (интегральная иммунология). М.: Либроком; 2009
  2. Dowlingand J.K., Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin. Translat. Immun. 2016; 5(5): e85.
  3. Wei L.J., Tan X., Fan G.J., Jiang Y.N., Shah Q.A. Role of the NOD1/NF-κB pathway on bovine neutrophil responses to crude lipopolysaccharide. Vet. J. 2016; 214: 24-31.
  4. Boland G., Beran J., Lievens M., Sasadeusz J., Dentico P., Nothdurft H., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine. 2004; 23(3): 316-20.
  5. Morefield G.L., Hawkins L.D., Ishizaka S.T., Kissner T.L., Ulrich R.G. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 2007; 14(11): 1499-504.
  6. Abbott A. Lyme disease: uphill struggle. Nature. 2006; 439(7076): 524-5.
  7. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A. et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine. 2006; 24(12): 2049-56.
  8. Miller R.L., Meng T.C., Tomai M.A. The Antiviral Activity of Toll-Like Receptor 7 and 7/8 Agonists. Drug News Perspect. 2008; 21(2): 68-79.
  9. Craft N., Birnbaum R., Quanquin N., Erfe M.C., Quant C., Haskell J. et al. Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice. Clin. Vaccine Immunol. 2014; 21(9): 1314-22.
  10. Sepehri Z., Kiani Z., Alavian S.M., Arababadi M.K., Kennedy D. The link between TLR7 signaling and hepatitis B virus infection. Life Sci. 2016; 158: 63-9.
  11. Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., Fuller A.E. et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002; 218(1-2): 74-86.
  12. Stokes J.R., Sorkness R.L., Kaplan M.R., Castleman W.L., Tomai M.A., Miller R.L., et al. Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur. Respir. J. 1998; 11(2): 324-9.
  13. Schön M., Schön M.P. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr. Med. Chem. 2007; 14(6): P681-7.
  14. Bernstein D.I., Harrison C.J. Effects of the Immunomodulating Agent R837 on Acute and Latent Herpes Simplex Virus Type 2 Infections. Antimicrob. Agents Chemother. 1989; 33(9): 1511-5.
  15. Reiter M.J., Testerman T.L., Miller R.L., Weeks C.E., Tomai M.A. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukoc. Biol. 1994; 55(2): 234-40.
  16. Miao X., Luo D., Min W., Lin X., Wang D., Xu Y., et al. Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro. Int. J. Dermatol. 2012; 51(9): 1116-22.
  17. Diamantis M.L., Bartlett B.L., Tyring S.K. Safety, efficacy and recurrence rates of imiquimod cream 5% for treatment of anogenital warts. Skin Therapy Lett. 2009; 14(5): 1-3, 5.
  18. Bechtel M.A., Trout W. Sexually Transmitted Diseases. Clin. Obstet. Gynecol. 2015; 58(1): 172-84.
  19. Gerster J.F. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use. Patent US № 4689338; 1987.
  20. Harrison L.I., Stoesz J.D., Battiste J.L., Nelson R.J., Zarraga I.E. A pharmaceutical comparison of different commercially available imiquimod 5% cream products. J. Dermatolog. Treat. 2009; 20(3): 1-5.
  21. Смирнов В.С., Петленко С.В. Сравнительное влияние топических препаратов имихимода на неповрежденную кожу морских свинок. Российский иммунологический журнал. 2016; 10(3): 346-8.
  22. Ашмарин И.П., Воробьев А.А. Статистические методы в микробиологических исследованиях Ленинград: Медгиз; 1962.
  23. Schacker T.W., Conant M., Thoming C., Stanczak T., Wang Z., Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents Chemother. 2002; 46(10): 3243-8.
  24. Kan Y., Okabayashi T., Yokota S., Yamamoto S., Fujii N., Yamashita T. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J. Virol. 2012; 86(19): 10338-46.
  25. van der Snoek E.M., den Hollander J.C., van der Ende M.E. Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions. Sex Transm. Infect. 2015; 91(4): 245-7.
  26. Harrison C.J., Jenski L., Voychehovski T., Bernstein D.I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 1988; 10(4-5): 209-23.
  27. Leeyaphan C., Surawan T.M., Chirachanakul P., Prasertworonun N., Punyaratabandhu P., Omcharoen V. et al. Cinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int. J. Infect. Dis. 2015; 33: 165-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Smirnov V.S., Petlenko S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies